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Background: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli cause up to 10% of catheter-
associated urinary tract infections (CAUTI). We report changes in ESBL prevalence among CAUTIs in an adult acute
care hospital from 2006-2012 and describe factors associated ESBL-production among E. coli CAUTI.
Findings: Data on patients ≥18 years discharged from a 647-bed tertiary/quaternary care hospital (2006-2012), a
221-bed community hospital (2007-2012), and a 914-bed tertiary/quaternary care hospital (2008) were obtained
retrospectively from an electronic database (N = 415,430 discharges). Infections were identified using a previously
validated electronic algorithm. Information on medical conditions and treatments were collected from electronic
health records and discharge billing codes. A case-control design was used to determine factors associated with
having a CAUTI caused by an ESBL-producing E. coli versus a non-ESBL-producing E. coli. Changes in yearly
proportion of ESBL E. coli CAUTI at the 647-bed tertiary/quaternary care hospital were evaluated. ESBL increased
from 4% in 2006 to 14% in 2012, peaking at 18% in 2009. Prior antibiotic treatment and urinary tract disease
significantly increased odds of ESBL.
Conclusions: This study provides evidence that treatment with beta-lactam and non-beta-lactam antibiotics is a risk
factor for acquiring ESBL-producing E. coli CAUTI, and the prevalence of this organism may be increasing in acute
care hospitals.
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Escherichia coli is the most common causative agent of
catheter-associated urinary tract infections (CAUTI; >20%)
[1]. Extended-spectrum beta-lactamase (ESBL)-producing
strains of E. coli, while representing a small percentage
(<10%), are particularly concerning because they confer re-
sistance to a myriad of antibiotics including penicillins and
third generation cephalosporins, and because their preva-
lence has been increasing in community and hospital set-
tings during recent years [2,3]. The purpose of this study is* Correspondence: bac2116@columbia.edu
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unless otherwise stated.to describe changes in prevalence and factors associated
with CAUTI caused by ESBL-producing E. coli in three
adult acute care hospitals from 2006 through 2012.Methods
Data on all patients ≥18 years discharged from three
New York City hospitals within a single network were
obtained retrospectively from a larger electronic data-
base as part of an NIH-funded study (Distribution of the
Costs of Antimicrobial Resistant Infections, NR010822).
The study was approved by the Institutional Review
Board of Columbia University Medical Center. Data
were available from 2006-2012 for a 647-bed tertiary/
quaternary care hospital, from 2007-2012 for a 221-bedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Percentage by year of Escherichia coli CAUTI which
were ESBL-positive in an adult tertiary/quaternary care
hospital, 2006-2012. Yearly change in proportion is significant
using Cochran-Armitage test for trend (p < 0.0001).
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tiary/quaternary care hospital (N = 415,430 discharges).
As described in detail in Apte et al. [4], the database
contained information from a number of electronic
sources, including patients’ electronic health, discharge,
laboratory, and medication administration records. The
discharge data provided admission and discharge dates,
International Classification of Diseases Ninth Revision
Clinical Modification (ICD-9-CM) codes for primary
and secondary diagnoses present on admission, age, gen-
der, comorbidities, and surgical procedures. The clinical
data sources provided time stamped information on
catheterization and medications.
CAUTI were defined based on National Healthcare
Safety Network (NHSN, http://www.cdc.gov/nhsn/about.
html) guidelines (positive urine culture >48 hours after
urinary catheterization) and identified using previously
validated computerized algorithms [4,5]. If a patient had
multiple CAUTIs during the study period, only the first
was included. We performed a case-control study to deter-
mine factors associated with having a CAUTI caused by
an ESBL-producing E. coli versus a non-ESBL-producing
E. coli. First, we determined the bivariable associations
between ESBL production and age, sex, comorbidities
including diabetes mellitus, HIV, urinary tract disease, and
malignancies, Charlson Comorbidity Index score (http://
www.uroweb.org/fileadmin/livesurgery/Charlson_Comor-
bidity_Index.pdf), urinary tract procedures, days of
catheterization, and antibiotic treatment received dur-
ing the patient’s hospitalization prior to infection onset.
All variables significantly associated (p ≤ 0.05) with
ESBL production were included in a multivariable logis-
tic regression model. We evaluated changes in yearly
proportion of ESBL E. coli CAUTI at the 647-bed ter-
tiary/quaternary care hospital, for which data were
available from 2006-2012, using the Cochran-Armitage
test for trend. All statistical analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC).Results
During the seven-year study period a total of 2,164 pa-
tients (1,616 women, 74.7%, and 548 men, 25.3%) devel-
oped a CAUTI with E. coli as the primary infecting
pathogen, and 271 (12.5%) were ESBL-producing. The
proportion of E. coli CAUTI that were ESBL-producers
in the 647-bed tertiary/quaternary care hospital increased
from 4% in 2006 to 14% in 2012, peaking at 18% in 2009
(p < 0.0001; Figure 1). Over half of patients with CAUTI
were diagnosed within 4 days of catheter insertion, over
three-quarters within 8 days, and over 98% (n = 2,123)
within 30 days. Descriptive characteristics and antibiotics
administered prior to CAUTI onset are summarized for
cases and controls in Table 1.Results of the case control study are presented in
Table 1. In the crude analyses, cases were significantly
older than controls (70.4 and 67.5 years, respectively) and
had greater Charlson Comorbidity scores (7.06 and 6.44,
respectively). Male sex, preexisting urinary tract disease,
having a urinary tract procedure, and longer duration of
catheterization prior to CAUTI onset were also associated
with increased odds of ESBL production. Receiving any
antibiotic prior to CAUTI onset was significantly associ-
ated with ESBL production, and six antibiotics specifically
were administered significantly more often in cases than
in controls: aminoglycosides, first-generation cephalo-
sporins, third-generation cephalosporins, macrolides,
fourth-generation penicillins, and vancomycin. In the
multivariable model, age, urinary tract disease, and receipt
of aminoglycosides, first-generation cephalosporins, macro-
lides, fourth-generation penicillins, and vancomycin were
significantly associated with ESBL production.
Discussion
Though several studies have examined risk factors for ESBL
emergence in hospitalized and non-hospitalized patients
with urinary tract infections (UTI), these studies were
community-based and not focused on catheterized patients
[2,3,6-8]. Since CAUTI may result in antibiotic susceptibil-
ity patterns different from those of non-catheter-related
UTI, understanding the prevalence trends and risk factors
for ESBL emergence unique to this population is important
for the development and implementation of effective pre-
vention efforts [9]. The prevalence of ESBL-producing
strains in this sample (12.2%) was slightly higher than
reported in previous studies which included both cathe-
terized and non-catheterized patients (7-10.9%) [6,7,10],
but the overall increase in ESBL prevalence over time is
consistent with other reports [2,3,10]. An analysis of
trends in gram-negative bacterial resistance among
patients with UTI from a nationally representative sam-
ple of US hospitals between 2000 and 2009 found a
Table 1 Factors associated with catheter-associated urinary tract infections caused by extended-spectrum beta-
lactamase (ESBL)-producing Escherichia coli versus non-ESBL-producing E. coli
Variable ESBL-producing E.
coli isolates (N = 271)
Non-ESBL-producing E.






Odds Ratio (95% CI)
Mean (range) age, in years 70.4 (24-98) 67.5 (18-103) 67.9 (18-103) *0.003b 1.01 (1.00, 1.02)
Gender (reference, female) 0.01 1.22 (0.91, 1.65)
Male (n (%)) 86 (31.7%) 462 (24.4%) 548 (25.3%)
Female (n (%)) 185 (68.3%) 1431 (75.6%) 1616 (74.7%)
HIV Positive 5 (1.9%) 12 (0.6%) 17 (0.8%) 0.052c 2.09 (0.66, 6.55)
Diabetes 89 (32.8%) 522 (27.6%) 611 (28.2%) 0.07 NA
Urinary Tract Disease 226 (83.4%) 1420 (75.0%) 1646 (76.1%) 0.003 1.43 (1.01, 2.03)
Malignancy 59 (21.8%) 363 (19.2%) 422 (19.5%) 0.31 NA
Mean (range) Duration of
Catheterization Prior to CAUTI
Onset, in days (Mean)
7.74 (0-78) 6.32 (0-124) 6.50 (0-124) *0.03b 0.99 (0.98, 1.01)
Urinary Tract Procedure 26 (9.59%) 113 (5.97%) 139 (6.42%) 0.02 1.43 (0.88, 2.32)
Mean (range) Charlson
Comorbidity Score
7.73 (0-35) 6.76 (0-51) 6.88 (0-51) 0.001d 1.03 (0.99, 1.06)
Antibiotics Received Prior to
CAUTI Onset
174 (64.2%) 804 (42.5%) 978 (45.2%) <0.0001 NA
Antibiotic received**
Aminoglycoside 27 (9.9%) 73 (3.9%) 100 (4.6%) <0.0001 5.42 (1.77, 16.55)
Cephalosporin, 1st Gen. 66 (24.4%) 346 (18.3%) 412 (19.0%) 0.02 2.34 (1.63, 3.36)
Cephalosporin, 3rd Gen. 23 (8.5%) 29 (1.5%) 52 (2.4%) <0.0001 2.89 (0.79, 10.67)
Macrolide 22 (8.1%) 69 (3.7%) 91 (4.2%) 0.001 2.39 (1.12, 5.08)
Penicillin, 2nd Gen. 17 (6.3%) 91 (4.8%) 108 (5.0%) 0.30 NA
Penicillin, 4th Gen. 50 (18.5%) 173 (9.1%) 223 (10.3%) <0.0001 2.65 (1.48, 4.76)
Vancomycin 59 (21.8%) 203 (10.7%) 262 (12.1%) <0.0001 3.40 (2.26, 5.12)
CAUTI, catheter-associated urinary tract infection; ESBL, extended-spectrum beta-lactamase; NA, not included in multivariable model.
aChi-Square test unless otherwise denoted; bT-test; cFisher’s Exact Test; dWilcoxon-Mann-Whitney Test.
*F-Test for Equality of Variances indicated unequal variance and appropriate p-value was used.
** In the multivariable model, antibiotics were examined as a seven-level categorical variable. Reference category: No antibiotics prior to CAUTI onset.
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similar to our results [3].
Our findings regarding risk factors for ESBL produc-
tion are also similar to those reported in previous studies
that included community-acquired UTIs and/or non-
catheter-associated hospital-acquired UTIs. In our sam-
ple of hospitalized, catheterized patients, we found a
strong positive association between prior treatment with
beta-lactam and non-beta-lactam antibiotics and ESBL
production, consistent with other studies of UTI caused
by E. coli [2,6,8]. Like most other studies, we failed to
detect significant differences in odds of ESBL by age,
gender, comorbid conditions, and overall severity of ill-
ness; however we did find a significant positive associ-
ation with urinary tract disease [6-8,10]. Patients who
undergo a urinary tract procedure or surgery may be at
greater risk for the emergence of resistance due in part
to longer catheterization periods and increased antibiotic
use. Nevertheless, urinary tract disease remained signifi-
cant even after adjustment for length of catheterizationand treatment with antibiotics, suggesting that it may
have an independent association with ESBL.
While this is one of the largest studies to focus on
CAUTI with ESBL-producing E. coli and document trends
in resistance over time, the research does have some limita-
tions. First, this study makes use of electronically available
data to identify infections, as well as to determine patients’
clinical risk factors and comorbid health conditions. Infor-
mation on preexisting health conditions was garnered from
medical billing data, which are not collected for the
purposes of research and may have low sensitivity and/or
specificity. Aside from potential misclassification, using
electronic data also prohibited us from reporting detailed
information on the resistance patterns exhibited by the iso-
lates. In addition, data on antimicrobial use was limited to
those prescribed during the patients’ hospitalizations. The
case-control study was restricted to three hospitals within
a single, geographically narrow network, possibly limiting
generalizability. Additionally, we were only able to investi-
gate trends over time at one hospital due to limited data
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consistent with NHSN guidelines of UTI onset >48 hours
after catheterization, it is possible that some patients were
bacteriuric prior to catheter insertion.
This study provides further evidence that treatment with
beta-lactam and non-beta-lactam antibiotics is a risk fac-
tor for acquiring ESBL-producing E. coli CAUTI. Urinary
tract disease is also identified as a risk factor, independent
of antibiotic treatment and length of catheterization. Con-
sistent with other reports, this study found an increase in
ESBL prevalence among CAUTI in recent years. Risk fac-
tors for ESBL emergence may be different in CAUTI than
in non-catheter-associated UTI.
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